Navigation Links
Double Eagle Holdings Chooses National Securities Corporation as Exclusive Investment Banker
Date:8/15/2011

AVENTURA, Fla., Aug. 15, 2011 /PRNewswire/ -- Double Eagle Holdings, Ltd (OTCQB: DEGH), announced today that it has retained National Securities Corporation as the company's exclusive investment banker to lead the company's next round of capitalization, as well as possible acquisition and strategic alliance transactions. Double Eagle Holdings is the parent company of Fuse Science, Inc. (www.fusescience.com), the developer of new, proprietary technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals.

Founded in 1947, National Securities Corporation is an international full service independent brokerage firm with a diverse base of retail and institutional clients. National Securities was founded in 1947 in Seattle, Washington with the goal of providing a full suite of financial products and services to its registered representatives and clients. National Securities and its subsidiaries are headquartered in New York City and Seattle and have a multitude of domestic and international offices that provide a broad range of securities brokerage, financial planning, and investment services, as well as corporate finance and investment banking services to corporations and businesses. The company operates in more than 70 locations throughout the United States and Europe through some 800 Registered Representatives.(www.nationalsecurities.com/investmentbanking.php)

Fuse Science just recently announced its strategy to advance its technology through several major categories ranging from energy drinks to aspirin and from vitamins to major pharmaceutical applications in partnership with the New England Consulting Group.

"We believe in recruiting the best for all facets of our business, and National Securities is a proven leader in working with emerging growth companies," added Brian Tuffin, Fuse Science President and Chief Operating Officer. "As an immediate priority, the National Securities team will lead our company's next round of financing, which will fully capitalize operations through our next stage of growth and allow us to bring Fuse Science's ground-breaking technology to market."

About Double Eagle Holdings

Double Eagle Holdings (OTCQB: DEGH.pk) is an innovative consumer products holding company and the parent company of Fuse Science, Inc. Based in Aventura, Florida, Fuse Science is the developer of patent-pending conveyance technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals, delivering their benefits faster and more effectively than ever before. Information about Fuse Science is available online at www.fusescience.com or by calling 305-503-FUSE (3873).

Safe Harbor Statement: Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the company's SEC filings. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.


'/>"/>
SOURCE Double Eagle Holdings, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. RediClinic Offers Affordable New Plan Clinically Shown to Double a Persons Chance to Stop Smoking
2. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
3. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
4. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
5. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
6. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
7. Gaining Too Much Weight During Pregnancy Nearly Doubles Risk of Having a Heavy Baby
8. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
9. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
10. Mayo Clinic Study Finds Younger Men With Erectile Dysfunction at Double Risk of Heart Disease
11. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... and Gynecology markets with innovative and proprietary products, will ... 31, 2017 after the market close on Tuesday, May ... a conference call and webcast to discuss its financial ... at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
(Date:4/18/2017)...  Astute Medical, Inc., developer of biomarkers for better ... at the 2017 National Kidney Foundation (NKF) Spring ... April 22. Physicians will present data on two biomarkers, ... for acute kidney injury (AKI) during the management of ... Elevated levels of TIMP-2 and IGFBP-7 have been ...
Breaking Medicine Technology:
(Date:4/27/2017)... ... 27, 2017 , ... Plastic Surgery Associates is excited to announce that Heather ... the upcoming Aesthetic Meeting. Held in San Diego, at the San Diego Convention Center, ... lend their expertise to the Premier Global Hot Topics session, speaking on genital rejuvenation. ...
(Date:4/26/2017)... ... April 26, 2017 , ... The ... Awards recipients, comprised of organizations and individuals who have stretched the boundaries ... 2017 President’s Awards recognize individuals and organizations on the forefront of healthcare ...
(Date:4/26/2017)... ... April 26, 2017 , ... The National Business ... National Registry of Emergency Medical Technicians and welcomes this organization to ... Dr. Jan G. West, Ph.D. , CEO & Organizational Psychologist at NBRI. “This ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want ... unique website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced plant breeding technology ... and better food, with fewer resources. It highlights the business’ principles, research and ...
(Date:4/25/2017)... ... ... Bellus Medical, a leader in medical aesthetics, recently acquired ... photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically formulated to ... minimize the appearance of pores – all with minimal downtime and results that ...
Breaking Medicine News(10 mins):